TY - JOUR
T1 - A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis
AU - On behalf of the Global Registry Harmonization Group
AU - Cosgriff, Rebecca
AU - Ahern, Susannah
AU - Bell, Scott C.
AU - Brownlee, Keith
AU - Burgel, Pierre Régis
AU - Byrnes, Cass
AU - Corvol, Harriet
AU - Cheng, Stephanie Y.
AU - Elbert, Alexander
AU - Faro, Albert
AU - Goss, Christopher H.
AU - Gulmans, Vincent
AU - Marshall, Bruce C.
AU - McKone, Edward
AU - Middleton, Peter G.
AU - Ruseckaite, Rasa
AU - Stephenson, Anne L.
AU - Carr, Siobhán B.
N1 - Publisher Copyright:
© 2020
PY - 2020/5
Y1 - 2020/5
N2 - Information is lacking on the clinical impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (CF). Our aim was to characterise SARS-CoV-2 infection in people with cystic fibrosis. Methods: Anonymised data submitted by each participating country to their National CF Registry was reported using a standardised template, then collated and summarised. Results: 40 cases have been reported across 8 countries. Of the 40 cases, 31 (78%) were symptomatic for SARS-CoV-2 at presentation, with 24 (60%) having a fever. 70% have recovered, 30% remain unresolved at time of reporting, and no deaths have been submitted. Conclusions: This early report shows good recovery from SARS-CoV-2 in this heterogeneous CF cohort. The disease course does not seem to differ from the general population, but the current numbers are too small to draw firm conclusions and people with CF should continue to strictly follow public health advice to protect themselves from infection.
AB - Information is lacking on the clinical impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (CF). Our aim was to characterise SARS-CoV-2 infection in people with cystic fibrosis. Methods: Anonymised data submitted by each participating country to their National CF Registry was reported using a standardised template, then collated and summarised. Results: 40 cases have been reported across 8 countries. Of the 40 cases, 31 (78%) were symptomatic for SARS-CoV-2 at presentation, with 24 (60%) having a fever. 70% have recovered, 30% remain unresolved at time of reporting, and no deaths have been submitted. Conclusions: This early report shows good recovery from SARS-CoV-2 in this heterogeneous CF cohort. The disease course does not seem to differ from the general population, but the current numbers are too small to draw firm conclusions and people with CF should continue to strictly follow public health advice to protect themselves from infection.
KW - Coronavirus
KW - Cystic fibrosis
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85084133315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084133315&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2020.04.012
DO - 10.1016/j.jcf.2020.04.012
M3 - Article
C2 - 32376098
AN - SCOPUS:85084133315
SN - 1569-1993
VL - 19
SP - 355
EP - 358
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 3
ER -